Add-on histamine receptor-3 antagonist for allergic rhinitis: A double blind randomized crossover trial using the environmental exposure unit

Allergy, Asthma and Clinical Immunology

Volumn 10, Issue 1, 2014, Pages

  North, Michelle L ^a,b   Walker, Terry J ^b   Steacy, Lisa M ^b   Hobsbawn, Barnaby G ^b   Allan, Richard J ^c   Hackman, Frances ^c   Sun, Xiaoqun ^b   Day, Andrew G ^b   Ellis, Anne K ^a,b  

^a QUEEN S UNIVERSITY   (Canada)

^b KINGSTON GENERAL HOSPITAL   (Canada)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Allergic rhinitis; Decongestant; Environmental exposure unit; Fexofenadine; H1 receptor; H3 receptor; Nasal congestion; PF 03654764; pseudoephedrine; Ragweed

Indexed keywords

FEXOFENADINE; HISTAMINE H3 RECEPTOR ANTAGONIST; PF 03654764; PSEUDOEPHEDRINE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADULT; ALLERGIC RHINITIS; ANXIETY; ARTICLE; BINDING AFFINITY; BODY TEMPERATURE; COGNITIVE DEFECT; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; ENVIRONMENTAL EXPOSURE; FATIGUE; FEMALE; HALLUCINATION; HEART PALPITATION; HOT FLUSH; HUMAN; HYPERHIDROSIS; HYPERTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MIGRAINE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; NIGHT SWEAT; NIGHTMARE; NOSE OBSTRUCTION; PARASOMNIA; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TACHYCARDIA; TOTAL NASAL SYMPTOM SCORE; UPPER ABDOMINAL PAIN;

EID: 84940278126     PISSN: 17101484     EISSN: 17101492     Source Type: Journal    
DOI: 10.1186/1710-1492-10-33     Document Type: Article

References (36)

1. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001, 108:S147-S334.
2. Phan H, Moeller ML, Nahata MC. Treatment of allergic rhinitis in infants and children: efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast. Drugs 2009, 69:2541-2576.
3. Simons FE. Comparative pharmacology of H1 antihistamines: clinical relevance. Am J Med 2002, 113(Suppl 9A):38S-46S.
4. del Cuvillo A, Mullol J, Bartra J, Davila I, Jauregui I, Montoro J, Sastre J, Valero AL. Comparative pharmacology of the H1 antihistamines. J Investig Allergol Clin Immunol 2006, 16(Suppl 1):3-12.
5. Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc 2007, 28:3-9.
6. Nathan RA, Meltzer EO, Derebery J, Campbell UB, Stang PE, Corrao MA, Allen G, Stanford R. The prevalence of nasal symptoms attributed to allergies in the United States: findings from the burden of rhinitis in an America survey. Allergy Asthma Proc 2008, 29:600-608.
7. Djukanovic R, Wilson SJ, Howarth PH. Pathology of rhinitis and bronchial asthma. Clin Exp Allergy 1996, 26(Suppl 3):44-51.
8. Chervinsky P, Nayak A, Rooklin A, Danzig M. Efficacy and safety of desloratadine/pseudoephedrine tablet, 2.5/120 mg two times a day, versus individual components in the treatment of patients with seasonal allergic rhinitis. Allergy Asthma Proc 2005, 26:391-396.
9. Moinuddin R, DeTineo M, Maleckar B, Naclerio RM, Baroody FM. Comparison of the combinations of fexofenadine-pseudoephedrine and loratadine-montelukast in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2004, 92:73-79.
10. Empey DW, Young GA, Letley E, John GC, Smith P, McDonnell KA, Bagg LR, Hughes DT. Dose-response study of the nasal decongestant and cardiovascular effects of pseudoephedrine. Br J Clin Pharmacol 1980, 9:351-358.
11. Stokes JR, Romero FA, Allan RJ, Phillips PG, Hackman F, Misfeldt J, Casale TB. The effects of an H3 receptor antagonist (PF-03654746) with fexofenadine on reducing allergic rhinitis symptoms. J Allergy Clin Immunol 2012, 129:409-412. 12 e1-2.
12. McLeod RL, Mingo GG, Kreutner W, Hey JA. Effect of combined histamine H1 and H3 receptor blockade on cutaneous microvascular permeability elicited by compound 48/80. Life Sci 2005, 76:1787-1794.
13. McLeod RL, Mingo GG, Herczku C, DeGennaro-Culver F, Kreutner W, Egan RW, Hey JA. Combined histamine H1 and H3 receptor blockade produces nasal decongestion in an experimental model of nasal congestion. Am J Rhinol 1999, 13:391-399.
14. Varty LM, Gustafson E, Laverty M, Hey JA. Activation of histamine H3 receptors in human nasal mucosa inhibits sympathetic vasoconstriction. Eur J Pharmacol 2004, 484:83-89.
15. Varty LM, Hey JA. Histamine H3 receptor activation inhibits neurogenic sympathetic vasoconstriction in porcine nasal mucosa. Eur J Pharmacol 2002, 452:339-345.
16. Daley-Yates P, Ambery C, Sweeney L, Watson J, Oliver A, McQuade B. The efficacy and tolerability of two novel H(1)/H(3) receptor antagonists in seasonal allergic rhinitis. Int Arch Allergy Immunol 2012, 158:84-98.
17. Wager TT, Pettersen BA, Schmidt AW, Spracklin DK, Mente S, Butler TW, Howard H, Lettiere DJ, Rubitski DM, Wong DF, Nedza FM, Nelson FR, Rollema H, Raggon JW, Aubrecht J, Freeman JK, Marcek JM, Cianfrogna J, Cook KW, James LC, Chatman LA, Iredale PA, Banker MJ, Homiski ML, Munzner JB, Chandrasekaran RY. Discovery of two clinical histamine H(3) receptor antagonists: trans-N-ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]cyclo-butanecarbox amide (PF-03654746) and trans-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]-N-(2-methylpropyl)cyc lobutanecarboxamide (PF-03654764). J Med Chem 2011, 54:7602-7620.
18. Day JH, Ellis AK, Rafeiro E, Ratz JD, Briscoe MP. Experimental models for the evaluation of treatment of allergic rhinitis. Ann Allergy Asthma Immunol 2006, 96:263-277. quiz 77-8, 315.
19. Ellis AK, Ratz JD, Day AG, Day JH. Factors that affect the allergic rhinitis response to ragweed allergen exposure. Ann Allergy Asthma Immunol 2010, 104:293-298.
20. Pfizer PF-03654764 Investigator's Brochure. Internal clinical and non-clinical studies 2009, Pfizer.
21. Norusis MJ. SPSS 11.0 Guide to Data Analysis. Chapter 22: Analyzing Residuals 2002, New Jersey: Prentice Hall.
22. Akerlund A, Andersson M, Leflein J, Lildholdt T, Mygind N. Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication. J Allergy Clin Immunol 2005, 115:S460-S482.
23. Day JH, Briscoe MP. Environmental exposure unit: a system to test anti-allergic treatment. Ann Allergy Asthma Immunol 1999, 83:83-89. quiz 9-93.
24. Ellis AK, Steacy LM, Walker T. Clinical Validation of Controlled Grass Pollen Challenge in the Environmental Exposure Unit (EEU) [abstract]. J Allergy Clin Immunol 2012, 129:AB112.
25. Deak AJ, Makra L, Matyasovszky I, Csepe Z, Muladi B. Climate sensitivity of allergenic taxa in Central Europe associated with new climate change related forces. Sci Total Environ 2013, 442:36-47.
26. Port A, Hein J, Wolff A, Bielory L. Aeroallergen prevalence in the northern New Jersey-New York City metropolitan area: a 15-year summary. Ann Allergy Asthma Immunol 2006, 96:687-691.
27. Dellavalle CT, Triche EW, Bell ML. Spatial and temporal modeling of daily pollen concentrations. Int J Biometeorol 2012, 56:183-194.
28. Jacobs RL, Harper N, He W, Andrews CP, Rather CG, Ramirez DA, Ahuja SK. Responses to ragweed pollen in a pollen challenge chamber versus seasonal exposure identify allergic rhinoconjunctivitis endotypes. J Allergy Clin Immunol 2012, 130:122-7 e8.
29. Day JH, Briscoe MP, Welsh A, Smith JN, Clark A, Ellis AK, Mason J. Onset of action, efficacy, and safety of a single dose of fexofenadine hydrochloride for ragweed allergy using an environmental exposure unit. Ann Allergy Asthma Immunol 1997, 79:533-540.
30. Berkowitz RB, Woodworth GG, Lutz C, Weiler K, Weiler J, Moss M, Meeves S. Onset of action, efficacy, and safety of fexofenadine 60 mg/pseudoephedrine 120 mg versus placebo in the Atlanta allergen exposure unit. Ann Allergy Asthma Immunol 2002, 89:38-45.
31. Weisler RH, Pandina GJ, Daly EJ, Cooper K, Gassmann-Mayer C. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. CNS Drugs 2012, 26:421-434.
32. Smit MJ, Timmerman H, Alewijnse AE, Leurs R. From histamine H2 receptor regulation to reclassification of H2 antagonists; inverse agonism as the basis for H2 receptor upregulation. Receptors Channels 1998, 5:99-102.
33. Bakker RA, Wieland K, Timmerman H, Leurs R. Constitutive activity of the histamine H(1) receptor reveals inverse agonism of histamine H(1) receptor antagonists. Eur J Pharmacol 2000, 387:R5-R7.
34. Wu RL, Anthes JC, Kreutner W, Harris AG, West RE. Desloratadine inhibits constitutive and histamine-stimulated nuclear factor-kappaB activity consistent with inverse agonism at the histamine H1 Receptor. Int Arch Allergy Immunol 2004, 135:313-318.
35. Monczor F, Fernandez N, Fitzsimons CP, Shayo C, Davio C. Antihistaminergics and inverse agonism: potential therapeutic applications. Eur J Pharmacol 2013, 715:26-32.
36. Wieland K, Bongers G, Yamamoto Y, Hashimoto T, Yamatodani A, Menge WM, Timmerman H, Lovenberg TW, Leurs R. Constitutive activity of histamine h(3) receptors stably expressed in SK-N-MC cells: display of agonism and inverse agonism by H(3) antagonists. J Pharmacol Exp Ther 2001, 299:908-914.